Diuretic Strategies in Acute Decompensated Heart Failure

被引:13
作者
Hardin E.A. [1 ]
Grodin J.L. [1 ]
机构
[1] Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, 75390-9047, TX
关键词
Acute decompensated heart failure; Decongestive; Diuretic; Heart failure;
D O I
10.1007/s11897-017-0319-y
中图分类号
学科分类号
摘要
Purpose of Review: The burden of heart failure in the United States is growing rapidly to epic proportions with serious clinical implications for patients and economic strain for healthcare systems. One of the most common reasons for hospitalization in acute decompensated heart failure (ADHF) is excess volume accumulation which leads to untoward symptoms including dyspnea,orthopnea, and edema. Recent Findings: Over the past several decades, there has been great interest in exploring various decongestive strategies in order to achieve symptomatic improvement and favorable clinical outcomes. These include different modalities of loop diuretic administration, the adjunctive use of non-loop diuretics, and other diuretic sparing strategies. Summary: Herein, we provide an appraisal of these decongestive strategies and discuss novel concepts predicting clinical outcomes based on diuretic response and decongestive adequacy while discussing commonly encountered problems such as worsening renal function in ADHF. © 2017, Springer Science+Business Media New York.
引用
收藏
页码:127 / 133
页数:6
相关论文
共 53 条
[11]  
Uchida T., Yamanaga K., Nishikawa M., Ohtaki Y., Kido H., Watanabe M., Anti-aldosteronergic effect of torasemide, Eur J Pharmacol, 205, pp. 145-150, (1991)
[12]  
Lopez B., Gonzalez A., Beaumont J., Querejeta R., Larman M., Diez J., Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure, J Am Coll Cardiol, 50, pp. 859-867, (2007)
[13]  
Lopez B., Querejeta R., Gonzalez A., Sanchez E., Larman M., Diez J., Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure, J Am Coll Cardiol, 43, pp. 2028-2035, (2004)
[14]  
Cosin J., Diez J., Torasemide in chronic heart failure: results of the TORIC study, Eur J Heart Fail, 4, pp. 507-513, (2002)
[15]  
Bikdeli B., Strait K.M., Dharmarajan K., Et al., Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives?, J Am Coll Cardiol, 61, pp. 1549-1550, (2013)
[16]  
Konecke L.L., Clinical trial of bumetanide versus furosemide in patients with congestive heart failure, J Clin Pharmacol, 21, pp. 688-690, (1981)
[17]  
Felker G.M., Lee K.L., Bull D.A., Et al., Diuretic strategies in patients with acute decompensated heart failure, N Engl J Med, 364, pp. 797-805, (2011)
[18]  
Schrier R.W., Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?, J Am Coll Cardiol, 47, pp. 1-8, (2006)
[19]  
Heywood J.T., Fonarow G.C., Costanzo M.R., Mathur V.S., Wigneswaran J.R., Wynne J., High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database, J Card Fail, 13, pp. 422-430, (2007)
[20]  
Damman K., Testani J.M., The kidney in heart failure: an update, Eur Heart J, 36, pp. 1437-1444, (2015)